Introduction {#s1}
============

The proportion of elderly people aged 65 years or older has exceeded 15% in developed countries, and it is expected to exceed 30% in 2050 ([@B1]). Physiological performance gradually decreases with aging, and frailty would be a severe burden in this population. Frailty affects activities of daily living (ADLs) and quality of life, resulting in frequent falls and walking problems. In addition, frailty is associated with mental and psychological problems, such as cognitive dysfunction and depression ([@B2], [@B3]). In recent years, several studies have reported on the relationship between motor dysfunction and frailty in Parkinson\'s disease (PD) ([@B4]--[@B7]). PD patients are likely to have frailty, and such patients are more prone to gait and balance problems than normal PD patients ([@B5], [@B6]).

Gait disturbance is a common problem among PD patients, and physical frailty is potentially attributable to the gait problem in PD. Atrophy and disability of erector spinae muscles have been reported to cause gait disturbance ([@B7], [@B8]). Trunk muscle activity plays an important role in stabilizing gait. In particular, the strength of the erector spinae muscles is highly correlated with physical activity levels ([@B9]). When the trunk leans forward during walking, a decrease in step length and an increase in cadence are observed ([@B10]). In addition, the strength of the erector spinae muscles is reduced in the leaning posture, resulting in reduced walking speed and a wide base of walking ([@B11]).

Chronic muscle disuse in physical frailty is associated with neuromuscular disorders including PD, especially in the elderly population. In contrast, resistance training is effective, but these active adaptations could not be achieved with neuromuscular electrical stimulation or traditional rehabilitation efforts alone ([@B6], [@B12]); thus, establishment of new treatment methods has been expected.

In the field of neurorehabilitation, the hybrid assistive limb (HAL; Cyberdyne Inc., Tsukuba, Japan) has been receiving growing attention. HAL is a robotic exoskeleton designed to facilitate movements and was developed based on the "interactive biofeedback" (iBF) hypothesis ([@B13]). Specifically, the movement of the robot is triggered by bioelectric signals (BESs) detected by surface electrodes, supporting spontaneous movement of impaired muscles generating sensory feedback. Several studies have demonstrated the efficacy and feasibility of HAL and single-joint HAL for select neurological disorders ([@B13], [@B14]). In this study, we used a model called HAL lumbar type for care support (HAL-CB02).

HAL-CB02 is designed to mitigate risks of back pain by reducing the stress that will be applied on the back. HAL-CB02 consists of an exoskeleton frame and a power unit. The exoskeleton frame is composed of molds and belts for attachment to the lower back and the thigh and incorporates a three-axis accelerometer for measuring the absolute angle of the torso of the wearer. The power unit is composed of angle sensors and actuators of both hip joints. BES is detected from the surface electrode affixed to the erector spinae muscles; when the hip joints shift from flexion to extension, the actuator generates torque in accordance with the activity of the erector spinae muscles. The generated torque is transmitted to the wearer through the exoskeleton frame and supports standing, lifting operation, etc. By adjusting the assistance level, HAL-CB02 provides support according to the difficulty level of the movement, and the burden on the lumbar is reduced. HAL-CB02 is lightweight, as it weighs 3.1 kg including its battery, and it is easy to assemble and operate. An overview of HAL-CB02 is shown in [Figure 1](#F1){ref-type="fig"}.

![Overview of HAL-CB02. **(A)** Overall picture of HAL-CB02. **(B)** The location of electrode detecting BES from the erector spinae muscles (dual white code), and the reference electrode is at the side (single green code). **(C,D)** Back and side views of the HAL-CB02 when fully attached. BES, bioelectric signals.](fneur-11-00215-g0001){#F1}

In a study using HAL for lumbar support (prototype of HAL-CB02), stress on the lumbar intervertebral disc during weight lifting was reduced ([@B15]). In addition, when HAL-CB02 was worn for lifting movements and snow shoveling, lumbar fatigue was significantly reduced and working efficiency was significantly improved ([@B16], [@B17]). In this context, we hypothesized that exercise with the assistance of HAL-CB02 would enable repetitive movements of core muscles under a reduced load and thus improve motor dysfunction associated with walking ability in frailty patients. We also considered that frailty patients would have muscle disuse and loss of muscle coordination in common regardless of coexistence of neurodegenerative diseases, and therefore, a robot-assisted core exercise regimen may be applied for patients with advanced PD that is often complicated with frailty. To address this hypothesis, we considered that comparing the response to the robot-assisted rehabilitation between frailty patients with and without PD is important to shed light on the relationship between frailty and PD. In this study, we aimed to test whether the core exercise and squats using the HAL-CB02 may improve the motor functions of the lower limb in frailty patients and to explore the optimal patient selection from the frailty cohort.

Materials and Methods {#s2}
=====================

Study Design
------------

We included elderly frailty patients with or without PD who experienced walking disability from the period between June 2017 and September 2019. In this study, frailty was diagnosed based on the definition of Fried et al. ([Table 1](#T1){ref-type="table"}). Frailty is diagnosed when three or more conditions in the criteria are met, while pre-frailty meets one or two conditions. In this study, we made diagnosis of the walking disability based on the self-report and the 10-m walking test (10 MWT) results showing approximately 10 s or longer. For the non-PD cohort, we included patients with frailty associated with lumbar spine problems such as lumbar canal stenosis and compression fracture. For the PD cohort, we included advanced PD patients at Hoehn and Yahr (H&Y) Stages III and IV in the on-medication state. All PD patients had been diagnosed and followed by movement disorders specialists (SF and YT). We excluded patients with severe dementia, acute bone fracture, spine problems requiring surgical treatment, severe cardiopulmonary diseases, and a physique to which the robot does not fit. We also excluded PD patients at H&Y Stage V and with severe dyskinesia.

###### 

Frailty-defining criteria.

  ---------------------------------------------------------------------------------
  **Criteria**            **Measurement**
  ----------------------- ---------------------------------------------------------
  Weight loss             Lost \>5 kg unintentionally in prior 12 months

  Exhaustion              Felt exhausted for no reason in last week (self-report)

  Low physical activity   Activity scale\
                          Male: \<383 kcal/week\
                          Female: \<270 kcal/week

  Slowness                Time \>10 s to walk 10 m at usual pace

  Weakness                Grip strength\
                          Male: \<26 kg\
                          Female: \<18 kg
  ---------------------------------------------------------------------------------

*Frailty: three or more criteria present*.

*Pre-frailty: one or two criteria present*.

*Robust: no criteria present*.

This prospective study was approved by our institutional review board, and informed consent was obtained from study subjects. Since this is the first report to test the feasibility of rehabilitation program using the HAL-CB02 for frailty cohorts, we included only limited numbers of patients.

All patients performed five sessions of exercise using HAL-CB02. Exercise for PD patients was performed with "on" medication. The exercise time was 20--30 min per session, and participants took a rest as needed. As core exercises, pelvic tilt and forward reach were performed 30 times each. Exercises involved awareness of the anteversion of the pelvis at the sitting position and stimulation of the erector spinae muscles. In the squat method, the feet were spread apart according to the width of the shoulder, and the angle from the heel to the feet was approximately 30°. Then, the participants slowly bend their knees so that the buttocks protrude backwards, being careful that the knees are within the toe level. The knee flexion angle is targeted for a half squat (90°), and if there is knee pain, quarter squats (45°) are allowed. Then, the participants slowly extend their knees and return to the standing position. The assist level of HAL-CB02 was adjusted according to the physical state of the participants. We allowed participants with low physical function to use handrails. The number of squats was not specified, and participants were allowed to perform squats until exhaustion. The states of exercises are shown in [Figure 2](#F2){ref-type="fig"}.

![HAL-assisted exercise. **(A,B)** In the core exercise, patients were instructed to repeat bend over **(B)** and upright **(A)** positions, with the upper body in a sitting position with a pole held by extended arms. **(C)** Squat exercise with the HAL. He is a staff of our hospital, and written informed consent was obtained for publication of this study and accompanying images. HAL, hybrid assistive limb.](fneur-11-00215-g0002){#F2}

To evaluate the efficacy of the exercise, we measured physical functions using the 10 MWT, step length, timed up-and-go (TUG) test, and 30 s chair stand test (CST-30), at four time points: baseline, following five exercise sessions, 1-, and 3-month follow-up. During gait evaluation, physical therapists support the patients to prevent falls as needed. In CST-30, the participants performed sit-to-stand movements from a chair completed with arms crossed over the chest and as many times as possible within 30 s. We measured pain levels using the visual analog scale (VAS) and assess whether pain does not occur with exercise. Participants performed core exercises and squats using HAL-CB02 for five sessions within 1 week. All PD patients were also evaluated "on" medication. Adverse events associated with robot rehabilitation were also recorded such as skin problems, exacerbation of pain, and muscle damage.

Statistical Analysis
--------------------

Scores at baseline, immediately after HAL-assisted exercise, and at 1- and 3-month follow-up were compared using Friedman\'s test and Wilcoxon signed-rank test for intragroup comparisons. For intergroup comparisons, the Mann--Whitney *U* test was used to compare the improvement rate from baseline. Values are presented as mean ± standard deviation. SPSS 24.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. A *p* \< 0.05 was considered significant. We also performed Friedman\'s test to test the null hypothesis of no change in the number of squats during the training period.

Results {#s3}
=======

We recruited 16 frailty patients including eight non-PD and eight PD patients. Baseline demographics are summarized in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. No significant differences in any demographic features were found between the two groups. All non-PD patients had a history of some chronic spine problems inclusive of lumbar canal stenosis (*n* = 5), vertebral compression fracture (*n* = 2), and spina bifida (*n* = 1). Peak dose dyskinesia potentially affecting robot-assisted exercise program was not observed in all PD participants. In the PD group, 1- and 3-month follow-up data could only be evaluated in five and four patients, respectively, due to accessibility to the follow-up clinic. All participants completed the HAL-assisted exercise successfully, without any adverse events, and the squat frequency increased significantly with each session (*p* \< 0.001) ([Figure 3](#F3){ref-type="fig"}).

###### 

Baseline demographics of two cohorts.

  -------------------------------------------------------------------------------------
                                 **Non-PD**         **PD**             ***p*-values**
  ------------------------------ ------------------ ------------------ ----------------
  *N*                            8                  8                  

  Age (years)                    73.8 ± 13.2        68.6 ± 8.3         0.161

  Sex                            Male 3 (37.5%)     Male 4 (50.0%)     0.614

                                 Female 5 (62.5%)   Female 4 (50.0%)   

  Disease duration (PD, years)   N/A                10.9 ± 7.1         

  H&Y stage (PD)                 N/A                III 3 (37.5%)\     
                                                    IV 5 (62.5%)       

  Weight (kg)                    58.0 ± 9.1         56.3 ± 13.8        0.959

  Height (cm)                    158.3 ± 8.9        159.9 ± 13.0       1.000

  BMI                            23.1 ± 2.4         21.8 ± 4.0         0.279

  10 MWT (s)                     35.5 ± 31.1        20.3 ± 13.3        0.328

  Step length (m)                0.33 ± 0.13        0.38 ± 0.16        0.645

  TUG (s)                        37.9 ± 30.9        19.5 ± 8.5         0.279

  CST-30 (times)                 4.0 ± 3.7          3.3 ± 2.2          0.645
  -------------------------------------------------------------------------------------

*10 MWT, 10 m walking test; BMI, body mass index; CST-30, 30 s chair stand test; H&Y stage, Hoehn and Yahr Stage; PD, Parkinson\'s disease; TUG, timed up and go test*.

*Measured values are presented as means ± standard deviation*.

###### 

Patient characteristics.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Non-PD group**   **PD group**                                                                                                                                    
  ------------------ -------------- ----------- ------------- ------------------------------- --- ------------ ----------- ------------- --------------------------- ---------
  1                  84             F           Frailty       Mild LCS                        1   75           F           Frailty       Lumbar spondylosis (L4,5)   III/IV

  2                  79             M           Pre-frailty   LCS s/p laminectomy             2   63           F           Pre-frailty   None                        IV/IV

  3                  87             F           Frailty       LCS s/p PLIF                    3   65           F           Pre-frailty   None                        III/III

  4                  46             F           Pre-frailty   Spina bifida                    4   61           M           Pre-frailty   None                        IV/IV

  5                  73             F           Frailty       Mild LCS                        5   60           M           Pre-frailty   None                        IV/IV

  6                  67             M           Pre-frailty   Vertebral compression fx (L2)   6   66           M           Pre-frailty   Mild LCS                    IV/IV

  7                  83             F           Pre-frailty   Vertebral compression fx (L5)   7   76           F           Frailty       None                        IV/IV

  8                  71             M           Pre-frailty   LCS s/p PLIF                    8   83           M           Frailty       Mild LCS                    III/III

                     73.8 ± 13.2    3 males\                                                      68.6 ± 8.3   4 males\                                              
                                    5 females                                                                  4 females                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*fx, fracture; H&Y stage, Hoehn and Yahr stage; LCS, lumbar canal stenosis; PD, Parkinson\'s disease; PLIF, posterior lumbar interbody fusion; s/p, status post*.

![Transition graph showing number of squats at each session. HAL, hybrid assistive limb; N, non-Parkinson\'s disease; P, Parkinson\'s disease.](fneur-11-00215-g0003){#F3}

Physical evaluations showed significant improvements. The measured median and interquartile range values (*p*-values compared with baseline) from the evaluation items of the non-PD group at baseline, post-HAL, and 1- and 3- month follow-up were as follows: 10 MWT values were 23.3 \[13.5, 46.3\] s at baseline, 15.9 \[10.8, 30.2\] s (*p* = 0.012) post-HAL, 16.3 \[10.2, 25.3\] s (*p* = 0.012) at 1-month follow-up, and 18.5 \[10.3, 34.6\] s (*p* = 0.012) at 3-month follow-up. Step length values were 0.38 \[0.19, 0.43\] m at baseline, 0.43 \[0.26, 0.49\] m (*p* = 0.012) post-HAL, 0.46 \[0.32, 0.53\] m (*p* = 0.012) at 1-month follow-up, and 0.41 \[0.24, 0.49\] m (*p* = 0.012) at 3-month follow-up. TUG values were 30.1 \[17.5, 47.0\] s at baseline, 18.3 \[11.3, 28.8\] s (*p* = 0.012) post-HAL, 20.5 \[11.0, 31.6\] s (*p* = 0.012) at 1-month follow-up, and 27.1 \[13.1, 42.6\] s (*p* = 0.093) at 3-month follow-up. CST-30 values were 4.5 \[0.0, 7.3\] times at baseline, 6.0 \[3.8, 8.3\] times (*p* = 0.017) post-HAL, 6.0 \[3.8, 9.5\] times (*p* = 0.011) at 1-month follow-up, and 7.5 \[3.8, 8.8\] times (*p* = 0.024) at 3-month follow-up ([Figure 4](#F4){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). In addition, three participants with frailty at baseline improved to pre-frailty at 1-month follow-up, and two of them were able to keep up even at 3-month follow-up. Also, two of the five participants with pre-frailty at baseline were "robust" at 1-month follow-up, and they maintained this state even at 3-month follow-up.

![Box plots depicting outcome measures in the non-PD group at baseline, post-HAL, and at 1- and 3-month follow-ups. FU, follow-up; HAL, hybrid assistive limb; PD, Parkinson\'s disease.](fneur-11-00215-g0004){#F4}

###### 

Details of clinical outcomes.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
                    **Non-PD group**   **PD group**                                                                                               
  ----------------- ------------------ ----------------- ----------------- ----------------- ---------------- ----------------- ----------------- -----------------
  10 MWT (s)        23.3\              15.9\             16.3\             18.5\             15.3\            9.6\              12.0\             10.4\
                    \[13.5, 46.3\]     \[10.8, 30.2\]\   \[10.2, 25.3\]\   \[10.3, 34.6\]\   \[10.6, 26.7\]   \[8.5, 13.3\]\    \[9.4, 13.8\]\    \[10.1, 10.9\]\
                                       (0.012)           (0.012)           (0.012)                            (\<0.001)         (0.001)           (0.006)

  Step length (m)   0.38\              0.43\             0.46\             0.41\             0.37\            0.51\             0.42\             0.52\
                    \[0.19, 0.43\]     \[0.26, 0.49\]\   \[0.32, 0.53\]\   \[0.24, 0.49\]\   \[0.28, 0.47\]   \[0.42, 0.60\]\   \[0.40, 0.48\]\   \[0.47, 0.57\]\
                                       (0.012)           (0.012)           (0.012)                            (\<0.001)         (0.001)           (0.003)

  TUG (s)           30.1\              18.3\             20.5\             27.1\             17.7\            14.0\             14.6\             11.7\
                    \[17.5, 47.0\]     \[11.3, 28.8\]\   \[11.0, 31.6\]\   \[13.1, 42.6\]\   \[12.9, 22.7\]   \[10.1, 20.2\]\   \[11.5, 17.8\]\   \[11.5, 18.3\]\
                                       (0.012)           (0.012)           (0.093)                            (\<0.001)         (0.002)           (0.136)

  CST-30 (times)    4.5\               6.0\              6.0\              7.5\              4.0\             6.5\              7.0\              9.0\
                    \[0.0, 7.3\]       \[3.8, 8.3\]\     \[3.8, 9.5\]\     \[3.8, 8.8\]\     \[2.3, 4.3\]     \[5.8, 8.3\]\     \[7.0, 9.0\]\     \[6.8, 11.8\]\
                                       (0.017)           (0.011)           (0.024)                            (0.001)           (0.001)           (0.006)

  VAS at rest       35.5\              8.0\              10.5\             23.0\                                                                  
                    \[23.3, 48.5\]     \[3.8, 16.3\]\    \[1.5, 14.0\]\    \[17.8, 28.5\]\                                                        
                                       (0.036)           (0.012)           (0.233)                                                                

  VAS in motion     49.0\              9.5\              11.0\             24.0\                                                                  
                    \[19.5, 55.3\]     \[4.5, 18.5\]\    \[5.8, 17.8\]\    \[10.8, 31.8\]\                                                        
                                       (0.017)           (0.028)           (0.176)                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

*10 MWT, 10 m walking test; CST-30, 30 s chair stand test; HAL, hybrid assistive limb; PD, Parkinson\'s disease; TUG, timed up-and-go test; VAS, visual analog scale*.

*Measured values are presented as median \[interquartile range\] and (p-values compared to baseline)*.

The measured median and interquartile range values (*p*-values compared with baseline) from the evaluation items of the PD group at baseline, post-HAL, and 1- and 3- month follow-ups were as follows: 10 MWT values were 15.3 \[10.6, 26.7\] s at baseline, 9.6 \[8.5, 13.3\] s (*p* \< 0.001) post-HAL, 12.0 \[9.4, 13.8\] s (*p* = 0.001) at 1-month follow-up, and 10.4 \[10.1, 10.9\] s (*p* = 0.006) at 3-month follow-up. Step length values were 0.37 \[0.28, 0.47\] m at baseline, 0.51 \[0.42, 0.60\] m (*p* \< 0.001) post-HAL, 0.42 \[0.40, 0.48\] m (*p* = 0.001) at 1-month follow-up, and 0.52 \[0.47, 0.57\] m (*p* = 0.003) at 3-month follow-up. TUG values were 17.7 \[12.9, 22.7\] s at baseline, 14.0 \[10.1, 20.2\] s (*p* \< 0.001) post-HAL, 14.6 \[11.5, 17.8\] s (*p* = 0.002) at 1-month follow-up, and 11.7 \[11.5, 18.3\] s (*p* = 0.136) at 3-month follow-up. CST-30 values were 4.0 \[2.3, 4.3\] times at baseline, 6.5 \[5.8, 8.3\] times (*p* = 0.001) post-HAL, 7.0 \[7.0, 9.0\] times (*p* = 0.001) at 1-month follow-up, and 9.0 \[6.8, 11.8\] times (*p* = 0.006) at 3-month follow-up ([Figure 5](#F5){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). In addition, two participants with frailty at baseline improved to pre-frailty at 1-month follow-up, and one of them was able to keep up even at 3-month follow-up. Also, two of the six participants with pre-frailty at baseline were "robust" at 1-month follow-up, and one of them maintained this state even at 3-month follow-up.

![Box plots depicting outcome measures in the PD group at baseline, post-HAL, and at 1- and 3-month follow-ups. FU, follow-up; HAL, hybrid assistive limb; PD, Parkinson\'s disease.](fneur-11-00215-g0005){#F5}

Moreover, the improvement values from the baseline of each evaluation item in the non-PD group and PD group were compared. In all evaluation items, significant differences between the two groups at all time points were not observed ([Figure 6](#F6){ref-type="fig"}).

![Box plots of intergroup comparison of improvement rates from baseline for non-PD and PD groups. FU, follow-up; HAL, hybrid assistive limb; PD, Parkinson\'s disease.](fneur-11-00215-g0006){#F6}

Pain levels were reduced with HAL-assisted exercise. All patients in the non-PD group had low back pain, but post-HAL, the pain was significantly reduced and the effect persisted even after 1-month follow-up; however, at 3-month follow-up, a statistically significant difference was not observed, even if the measured value was higher than the baseline. In the PD group, no patients complained of low back pain, and pain related to HAL-assisted exercise was not reported. In the non-PD group, measured median and interquartile range values (*p*-values compared with baseline) of VAS score at rest and in motion at baseline, post-HAL, at 1- and 3-month follow-up were as follows: VAS scores at rest were 35.5 \[23.3, 48.5\] at baseline, 8.0 \[3.8, 16.3\] (*p* = 0.036) post-HAL, 10.5 \[1.5, 14.0\] (*p* = 0.012) at 1-month follow-up, and 23.0 \[17.8, 28.5\] (*p* = 0.233) at 3-month follow-up. VAS scores in motion were 49.0 \[19.5, 55.3\] at baseline, 9.5 \[4.5, 18.5\] (*p* = 0.017) post-HAL, 11.0 \[5.8, 17.8\] (*p* = 0.028) at 1-month follow-up, and 24.0 \[10.8, 31.8\] (*p* = 0.176) at 3-month follow-up ([Figure 4](#F4){ref-type="fig"} and [Table 4](#T4){ref-type="table"}).

Discussion {#s4}
==========

To the best of our knowledge, this study is the first to use HAL-CB02 in frailty and PD patients. HAL-CB02 may improve motor function. This result has the potential to improve frailty from a long-term perspective and clarified the feasibility of HAL-assisted exercise. One advantage of the robot rehabilitation is that the robot enables repeated performance of the same movements that are usually difficult to assist manually. We speculate that robot rehabilitation improves motor coordination by controlling axial muscles.

There are several reports of robot-assisted gait training (RAGT) for PD. Cappecci et al. reported that RAGT significantly improved endurance, gait capacity, motor symptoms, quality of life, and freezing gait ([@B18]). In addition, Alwardat et al.\'s meta-analysis reported that RAGT showed better outcomes than conventional interventions in some motor aspects of PD ([@B19]). Robot-assisted rehabilitation enables standardized treatment regardless of the therapists\' experience and repetitive exercise without patient\'s fatigue as shown in our results. Most of the reported RAGTs are based on gait assist robots, but we anticipate that HAL-CB02, as a treatment with core exercise and squats, can be performed more easily and safely. Concerning the similar improvements in two cohorts in our study, there are several explanations.

In this study, both PD and non-PD patients showed significantly improved motor function. In addition, since no significant difference was found between these two groups in terms of the improvement rate, it is expected that patients with physical frailty may have the same motor dysfunction regardless of the presence or absence of PD. From the standing point, we consider that the disturbance of the central pattern generator (CPG) in the spinal cord exists in common among frailty patients. Repetitive sensory feedback from HAL training may activate the central nervous system (CNS) and possibly induce neuroplasticity in the spinal cord level to facilitate functional recovery in the disused neuronal networks ([@B20]) ([Figure 7](#F7){ref-type="fig"}).

![Central nervous system activation by sensory feedback from hybrid assistive limb-assisted training. **(A)** Central nervous system (CNS) lesion resulted in gait disability. **(B)** The hybrid assistive limb (HAL) assisted core function, and sensory input was sent back to the CNS levels to activate the brain and the central pattern generator in the spinal cord. **(C)** In turn, the damaged CNS generated improved descending signals to the muscle for better locomotion.](fneur-11-00215-g0007){#F7}

Although there may be common factors for improvement among non-PD and PD cohorts, another factor may contribute to the improvement differently. We speculate that arthrogenic muscle inhibition (AMI) may be also related as a cause of failure of conventional rehabilitation of frailty patients, especially in a non-PD cohort with back pain. AMI is defined as the suppression of motor neurons due to trauma and the associated pain, resulting in decreasing muscle function. It is thought that abnormality of proprioceptive receptors due to swelling, inflammation, pain, and joint laxity causes AMI ([@B21], [@B22]). AMI is a reflexive response that acts as a protective mechanism to prevent further damage to the joint ([@B23]). AMI is the result of many different joint receptor activities. It acts on inhibitory interneurons that form synapses in the motor neuron pool of articular muscle tissue ([@B24]). Rice et al. proposed three spinal reflex pathways related to AMI: the group I non-reciprocal (Ib) inhibitory pathway, flexion reflex, and gamma (γ)-loop. When abnormality occurs in the peripheral joints and changes the afferent discharge from proprioceptive receptors, these spinal reflex pathways are impaired ([@B21]). Furthermore, joint afferents are susceptible to changes in discharge ([@B25], [@B26]), and the spinal descending pathway may strongly influence interneurons and motor neurons at the spinal level ([@B27]--[@B29]). Several studies have described the relationship between spinal reflex and AMI ([@B21], [@B30]), and proprioceptive sensory feedback is related to reflex inhibition ([@B31], [@B32]). Although AMI was reported to be related to lower-limb functions in many cases, Russo et al. reported that AMI of paravertebral muscles was easily affected by damage to the lumbar region ([@B33]). As described above, it is speculated that physical frailty patients easily develop neuromuscular disorders and are prone to dysfunction of the erector spinae muscles, and they are likely to have AMI.

An effective treatment for AMI includes biofeedback therapy ([@B34], [@B35]). Most of the reports are based on electromyographic biofeedback, which measures the electrical activity of the muscle from the electrodes attached to the skin surface and feeds back the magnitude of the muscle activity visually and auditorily ([@B36]--[@B41]). Similarly, in this study, we consider that biofeedback with HAL-CB02 had improved AMI. We considered that HAL-assisted exercise stimulates proper proprioceptive receptors by repeatedly feeding back correct motion at low load and suppresses abnormal spinal reflexes. Actually, our group has shown the possibility of AMI improvement by HAL-assisted exercise in patients who underwent total knee arthroplasty ([@B42], [@B43]). Similarly, our non-PD patients showed significant pain reduction following HAL-assisted exercise, and this may partly contribute to the improvement in motor functions.

As limitations of this study, we did not evaluate ADL, quality of life, and objective measures such as electromyograms, so we could not identify the clinical impact and cause of improvement. Since the subjects with only exercise without HAL-CB02 were not recruited as control, we could not measure the efficacy of the robot-assisted exercise. Furthermore, the sample size was small, and several patients in the PD group were unable to complete follow-up evaluation. Future investigation on these issues with an increased number of cases is necessary to confirm our findings.

Conclusions {#s5}
===========

Our results suggest that biofeedback therapy with HAL-CB02 may be a safe and promising treatment for patients with physical frailty even complicated with spine problems. In addition, motor dysfunction in PD patients may be partly due to physical frailty, and biofeedback therapy with HAL-CB02 is proposed as a treatment option. Immediate and sustained effects on patients who were refractory to conventional rehabilitation could provide evidence that changes in input to specific receptors by HAL-CB02 contribute to activation of disused neuronal networks and amelioration of AMI. Further long-term follow-up studies with an increased number and control cohort of conventional rehabilitation are warranted.
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